168 related articles for article (PubMed ID: 36434065)
1. Biological drivers of clinical phenotype in myelofibrosis.
Mascarenhas J; Gleitz HFE; Chifotides HT; Harrison CN; Verstovsek S; Vannucchi AM; Rampal RK; Kiladjian JJ; Vainchenker W; Hoffman R; Schneider RK; List AF
Leukemia; 2023 Feb; 37(2):255-264. PubMed ID: 36434065
[TBL] [Abstract][Full Text] [Related]
2. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
3. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Vachhani P; Verstovsek S; Bose P
Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
[TBL] [Abstract][Full Text] [Related]
4. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
Chifotides HT; Verstovsek S; Bose P
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444441
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F; Breccia M; Mazzoni C; Auteri G; Elli EM; Trawinska MM; Polverelli N; Tiribelli M; Benevolo G; Iurlo A; Tieghi A; Heidel FH; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Biondo M; Venturi M; Scaffidi L; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Bartoletti D; Paglia S; Vianelli N; Cavo M; Bonifacio M; Palumbo GA
Cancer; 2023 Jun; 129(11):1704-1713. PubMed ID: 36932983
[TBL] [Abstract][Full Text] [Related]
6. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.
Marcellino BK; Verstovsek S; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):415-421. PubMed ID: 32199764
[TBL] [Abstract][Full Text] [Related]
7. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
8. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
Kuykendall AT; Mo Q; Sallman DA; Ali NA; Chan O; Yun S; Sweet KL; Padron E; Lancet JE; Komrokji RS
Cancer; 2022 Oct; 128(19):3495-3501. PubMed ID: 35942592
[TBL] [Abstract][Full Text] [Related]
9. The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.
Rumi E; Trotti C; Vanni D; Casetti IC; Pietra D; Sant'Antonio E
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255170
[TBL] [Abstract][Full Text] [Related]
10. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein BL; Swords R; Hochhaus A; Giles F
Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
[TBL] [Abstract][Full Text] [Related]
11. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide.
Tremblay D; Baine I; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1067-e1074. PubMed ID: 36117043
[TBL] [Abstract][Full Text] [Related]
13. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
14. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
Mascarenhas J
Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
[TBL] [Abstract][Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
[TBL] [Abstract][Full Text] [Related]
16. Impact of molecular profiling on the management of patients with myelofibrosis.
Pastor-Galán I; Martín I; Ferrer B; Hernández-Boluda JC
Cancer Treat Rev; 2022 Sep; 109():102435. PubMed ID: 35839532
[TBL] [Abstract][Full Text] [Related]
17. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract][Full Text] [Related]
18. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
[TBL] [Abstract][Full Text] [Related]
19. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
20. Mutational profiling in myelofibrosis: implications for management.
Bose P; Verstovsek S
Int J Hematol; 2020 Feb; 111(2):192-199. PubMed ID: 31630335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
